Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 2/20 | 0.66 |
| ▸ | GLRA2 | P23416 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | GUSB | P08236 | 1/20 | 0.66 |
| ▸ | PTAFR | P25105 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13702705 | 1.00 | KDM4E (1.00) | KDM4EMAPK1GLRA1GLRA2CYP2C9 | |
| SCHEMBL16452771 | 1.00 | KDM4E (1.00) | KDM4EMAPK1GLRA1GLRA2CYP2C9 | |
| SCHEMBL30331275 | 1.00 | KDM4E (1.00) | KDM4EMAPK1GLRA1GLRA2CYP2C9 | |
| SCHEMBL500085 | 1.00 | KDM4E (1.00) | KDM4EMAPK1GLRA1GLRA2CYP2C9 | |
| SCHEMBL16653652 | 1.00 | KDM4E (1.00) | KDM4EMAPK1GLRA1GLRA2CYP2C9 | |
| SCHEMBL13960092 | 1.00 | KDM4E (1.00) | KDM4EMAPK1GLRA1GLRA2CYP2C9 | |
| SCHEMBL14078020 | 1.00 | KDM4E (1.00) | KDM4EMAPK1GLRA1GLRA2CYP2C9 | |
| SCHEMBL13702832 | 1.00 | KDM4E (1.00) | KDM4EMAPK1GLRA1GLRA2CYP2C9 | |
| SCHEMBL14078047 | 0.94 | KDM4E (0.88) | KDM4EMAPK1GLRA1GLRA2CYP2C9 | |
| SCHEMBL13960101 | 0.93 | KDM4E (0.86) | KDM4EMAPK1GLRA1GLRA2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 812 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622941-B2 | Anticoccidial composition comprising ginkgo leaves and use thereof | CJ CHEILJEDANG CORPORATION (KR) | 2026-05-12 | — | — | US | claimed |
| CN-122012537-A | Gene GbCYP A6 for promoting synthesis of ginkgolide and application thereof | 扬州大学 | 2026-05-12 | — | — | CN | claimed |
| EP-3782619-B1 | USE OF GINKGO BILOBA TERPENE LACTONE IN PREPARATION OF DRUGS FOR PREVENTION AND/OR TREATMENT OF TREMORS AND HEALTHCARE PRODUCTS | CHENGDU BAIYU PHARMACEUTICAL CO LTD (CN) | 2026-02-25 | — | — | EP | claimed |
| US-12545694-B2 | Cannabidiol derivatives, preparation method thereof and use thereof | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2026-02-10 | — | — | US | claimed |
| EP-4088723-B1 | CANNABIDIOL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CHENGDU BAIYU PHARMACEUTICAL CO LTD (CN) | 2025-08-06 | — | — | EP | claimed |
| CN-117269404-B | Thin-layer chromatography identification method of gingko seed formula particles and stir-fried gingko seed formula particles | 四川新绿色药业科技发展有限公司 | 2025-05-02 | — | — | CN | claimed |
| CN-119907666-A | Application of ginkgolide in preparing medicament for preventing or treating diabetes and diabetic complications | 成都百裕制药股份有限公司 | 2025-04-29 | — | — | CN | claimed |
| US-12285488-B2 | Oral dosage form containing theobromine-free cocoa | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-04-29 | — | — | US | claimed |
| WO-2025073211-A1 | METHOD FOR IDENTIFYING GINKGO FORMULA GRANULES AND FRIED GINKGO FORMULA GRANULES BASED ON THIN-LAYER CHROMATOGRAPHY | 四川新绿色药业科技发展有限公司 | 2025-04-10 | — | — | WO | claimed |
| US-20250082703-A1 | GINKGO BILOBA KETONE ESTER CAPSULE AND PREPARATION METHOD THEREOF | SPH XING LING SCI. & TECH. PHARMACEUTICAL CO., LTD. (CN) | 2025-03-13 | — | — | US | claimed |
| WO-1999020291-A9 | PHARMACEUTICAL GRADE GINKGO BILOBA | PHARMAPRINT INC (US) | 1999-08-12 | — | — | WO | claimed |
| WO-1999026643-A1 | METHODS OF PREPARATION OF BIOGINKGO | PHARMANEX, INC. (US) | 1999-06-03 | — | — | WO | claimed |
| WO-1999020291-A2 | PHARMACEUTICAL GRADE GINKGO BILOBA | PHARMAPRINT, INC. (US) | 1999-04-29 | — | — | WO | claimed |
| US-5599950-A | Preparation process of ginkgolide B from ginkgolide C | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) | 1997-02-04 | — | — | US | claimed |
| EP-0680968-A1 | Method for the preparation of ginkgolide B from ginkgolide C | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1995-11-08 | — | — | EP | claimed |
| US-5241084-A | PREPARATION PROCESS OF GINKGOLIDE B FROM GINKGOLIDE C | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1993-08-31 | — | — | US | claimed |
| EP-0532512-A4 | USE OF PLATELET ACTIVATING FACTOR ANTAGONISTS AS ANTI-PRURITIC AGENTS | — | 1993-05-05 | — | — | EP | claimed |
| EP-0532512-A1 | USE OF PLATELET ACTIVATING FACTOR ANTAGONISTS AS ANTI-PRURITIC AGENTS. | ALLERGAN INC (US) | 1993-03-24 | — | — | EP | claimed |
| WO-1991018608-A1 | USE OF PLATELET ACTIVATING FACTOR ANTAGONISTS AS ANTI-PRURITIC AGENTS | ALLERGAN, INC. (US) | 1991-12-12 | — | — | WO | claimed |
| US-4734280-A | PLATELET ACTIVATING FACTOR; ANTISHOCK AGENTS, GINKOLIDES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1988-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545694-B2 | Cannabidiol derivatives, preparation method thereof and use thereof | CNR1, CNR2, OPRM1 | KDM4E 4100/4885MAPK1 1016/4885GLRA1 132/4885 |
| US-12622941-B2 | Anticoccidial composition comprising ginkgo leaves and use thereof | ALPI, SI, SLC10A2 | KDM4E 2282/4885MAPK1 3048/4885GLRA1 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.